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Chronic inflammation is a feature of obesity and enhances the risk of atherosclerosis, cancer, 
diabetes, and autoimmunity. Specifically, pro-inflammatory Th17 and Th1 CD4
+
 effector T cells 
are increased in metabolic diseases. However, a clear molecular mechanism linking metabolic 
changes with pro-inflammatory T cells is lacking. We hypothesize that elevated levels of O-
linked β-N-acetylglucosamine (O-GlcNAc), a post-translational modification of nuclear and 
cytoplasmic proteins, promotes pro-inflammatory CD4+ T cell function. Since production of O-
GlcNAc involves input from carbohydrate, amino acid, fatty acid, and nucleic acid metabolism, 
the modification acts as a general sensor of a cell’s nutritional status. To investigate the role of 
O-GlcNAc in CD4+ T cell function, we treated CD4+ T cells with Thiamet-G (TMG, an 
inhibitor of the enzyme that removes O-GlcNAc (O-GlcNAcase, OGA)) before activation of the 
cells without addition of polarizing cytokines.  After culturing for four days and then re-
stimulating the cells for 24 hours, we found that these non-polarized CD4+ T cells produced 
significantly more pro-inflammatory IL-17A by both protein  and transcript levels.  Since IL-
17A is critically involved in exacerbating obesity-related pathology, such as atherosclerosis and 
insulin resistance, we next looked for an effect of O-GlcNAcylation in metabolic disease.  To 
investigate the role of O-GlcNAc in a setting of metabolic disease, we analyzed O-GlcNAc 
levels in CD4
+
 T cells from mice fed a high fat and cholesterol “Western” diet.  Naïve CD4+ T 
cells from obese mice have elevated O-GlcNAc levels compared to cells from mice fed standard 
chow.  When polarized to a Th17 lineage, cells from obese mice secrete more IL-17A, the 
eponymous Th17 cytokine.  Importantly, when naïve CD4+ T cells from lean and obese mice are 
polarized to a Th17 lineage in the presence of TMG, the cells from lean mice secrete levels of 
IL-17 comparable to those from obese mice.  Moreover, IL-17A secretion was exacerbated in 
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cells from obese mice.  Transcript levels of IL-17 are similarly elevated in both lean and obese 
mice Th17 cells treated with TMG.  Importantly, these results are recapitulated in human CD4+ 
T cells treated with TMG, suggesting a similar mechanism may operate in both mice and 
humans.  RORγt (retinoic acid-related orphan receptor gamma) acts as the Th17 master 
transcription factor, orchestrating the Th17 differentiation program.  While protein and transcript 
levels of RORγt did not change in the presence of TMG, chromatin immunoprecipitation 
demonstrated enhanced RORγt association with the IL-17 promoter and an enhancer, CNS2 
(conserved noncoding sequence 2) with TMG treatment.  Uniquely among the CD4
+
 effector T 
cell master transcription factors, RORγt is regulated by lipid ligands that promote or repress its 
activity.  We performed a broad lipidomics analysis on T cells and discovered that sterols and 
saturated fatty acids, known activating ligands of RORγt, were increased with TMG treatment.  
An investigation of potential mechanisms underlying these changes in lipid content in T cells 
revealed that the rate-limiting enzyme in fatty acid synthesis, ACC1, is O-GlcNAcylated in the 
carboxyltransferase and central region domains, which are important for catalytic conversion of 
acetyl CoA to malonyl CoA.  Collectively, our data suggest that elevated O-GlcNAc levels 
increase pro-inflammatory IL-17 secretion from Th17 cells through alteration of the lipidome 
and retention of RORγt at the IL-17 promoter complex.  These studies provide a potential 
molecular link between nutritional excess and Th17 differentiation and function.  Further study 
of these molecular mechanisms will provide insight into the link between O-GlcNAcylation and 
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 CHAPTER 1: INTRODUCTION  
Reprinted with permission from Machacek, M., Slawson, C., and Fields, P. E. (2018) O-GlcNAc: 
a novel regulator of immunometabolism. Journal of Bioenergetics and Biomembranes.  
 
The immune system is composed of a host of widely distributed and extremely dynamic cells 
capable of expanding and contracting rapidly in response to a myriad of microbial and 
environmental threats.  Within this complex network of cells, CD4
+
 T cells orchestrate the 
adaptive immune response’s elimination of a pathogen in a highly specific manner.  Among their 
many functions, CD4
+
 T cells dictate which class of immunoglobulin is expressed by B cells, 
enhance phagocytic function of innate immune cells like macrophages, and themselves 
differentiate into various effector cells specialized to eliminate specific classes of pathogens (1).  
Due to the dynamic and highly proliferative nature of CD4
+
 T cells, a fascinating question about 
their biology has emerged:  How can metabolism—another highly dynamic cellular process—
influence their function?  The burgeoning field of immunometabolism seeks to understand how 
the metabolic state of immune cells alters function and may be targeted or manipulated for 
therapeutic purposes.  An intriguing target in elucidating how metabolism alters immune cell 
function is the dynamic post-translational protein modification O-GlcNAc (O-linked N-
acetylglucosamine).  Since O-GlcNAc levels fluctuate as the metabolic state of the cell changes, 
O-GlcNAc is an appealing explanation for how a cell integrates extra- and intra-cellular 
metabolic signals to modify cytoplasmic, nuclear, and mitochondrial enzymes and subsequently 
alter cellular function.  Indeed, O-GlcNAcylation is critical for T cell activation (2,3), and when 
aberrant, contributes to inflammatory diseases (4-6). 
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Distinct metabolic programs are critical during T cell activation 
In lymph nodes, naïve CD4
+
 T cells are activated by antigen presenting cells (APC), such as 
dendritic cells, expressing major histocompatibility complex II (MHC II) loaded with an 
antigenic peptide on their cell surface.  Activation requires recognition of this peptide-MHC II 
complex by the clonally unique T cell receptor (TCR).  In addition to this first signal, a second 
signal is required to stimulate optimal proliferation of that particular T cell receptor-bearing 
clone.  This second signal is provided by a co-stimulatory molecule, such as CD28.  With these 
two signals, a T cell is now activated to respond specifically to the pathogen loaded onto the 
MHC II complex.  Activation triggers massive proliferation of the T cell and thus requires a 
tremendous influx of metabolites to sustain initial cell growth and subsequent multiple cell 



































Hexosamine Biosynthetic Pathway 
Figure 1. T cell activation induces cell surface expression of GLUT1 and amino acid 
transporters, facilitating uptake of glucose and glutamine.  This enhanced nutrient state 
provides substrates that directly feed into the hexosamine biosynthetic pathway (HBP), 
driving increased UDP-GlcNAc synthesis and protein O-GlcNAcylation by O-GlcNAc 
transferase (OGT).  
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Upon activation, naïve CD4
+
 T cells switch from relying primarily on oxidative phosphorylation 
for their metabolic needs to aerobic glycolysis and glutaminolytic programs.  With this switch 
comes an influx of metabolites capable of fueling cell growth and proliferation.  For example, 
early studies identified a sudden influx of glucose into activated T cells (7).  This initial 
observation has been further expanded upon by studies showing that activation triggers the 
upregulation of GLUT1 on the T cell surface.  This upregulation is mediated through the CD28 
co-stimulatory signaling pathway that engages the PI3K-AKT signaling cascade as well as 
MYC-mediated transcriptional activation of glycolytic genes (8-10).  In addition to increased 
glucose, activated T cells also require more amino acids.  TCR and CD28 engagement increases 
expression of amino acid transporters, particularly those needed for the import of leucine and 
glutamine (11,12).  Activated T cells have a nearly essential requirement for glutamine as an 
energy source (13)—increasing uptake of this particular amino acid ten times more than any 
other amino acid (14).  Besides being necessary for increased protein translation, glutamine is a 
versatile building block for many other cellular metabolites, including nucleotides via the de 
novo synthetic pathway and serving as an anaplerotic source of oxaloacetate (OAA) in the TCA 
cycle (15).  By replenishing OAA, citrate can be continuously generated and transported out of 
the mitochondria, where it is converted to acetyl CoA, the foundational building block for fatty 
acid and cholesterol synthesis.  Essentially, conversion of glutamine to acetyl CoA provides the 
building block required for increased fatty acid synthesis during T cell activation.  This step is 
critical since activated effector T cells favor de novo synthesis rather than exogenous uptake of 
fatty acids (10).  Overall, T cell activation induces major metabolic shifts, resulting in the cell 
switching from oxidative phosphorylation and fatty acid oxidation for its energetic needs to 
aerobic glycolysis, glutaminolysis, increased pentose phosphate pathway flux, and de novo lipid 
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generation.  This substantial change in metabolism is thought to be required to meet the cell’s 
new, increased metabolic demands.  Importantly, these metabolic pathways all produce 
substrates required in the hexosamine biosynthetic pathway for UDP-GlcNAc synthesis and thus 
protein O-GlcNAcylation (Figure 1). 
Intrinsic and external metabolic factors are required for specific CD4+ T cell 
differentiation and function 
 
In addition to providing the stimuli needed for T cell activation, cytokines secreted by the 
antigen-presenting cell during activation will direct CD4
+
 T cell differentiation into one of at 
least six classes of specialized effectors.  The four “main” classes of effectors are 1) T helper 1 
(Th1), which target intracellular and viral pathogens; 2) Th2, which target helminths; 3) Th17, 
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Figure 2.  Cytokines secreted by antigen presenting cells (APC) induce signaling 
through STAT proteins, which upregulate a lineage-defining transcription factor.  This 
“master” transcription factor then induces transcription of cytokines that carry out the 
specialized function of the T cell.  Th1, Th2, and Th17 have effector functions in 
eliminating specific classes of pathogens, but over-activity can lead to disease.  
Inducible Tregs serve an opposing function in diminishing effector T cell responses.   
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which target fungal and extracellular bacteria; and 4) inducible regulatory T cells (iTregs), which 
have an opposing function in decreasing the inflammatory immune response (Figure 2).  Th1, 
Th2, and Th17 are often categorized as “effectors” due to their vital function in eliminating 
specific classes of pathogens, while regulatory T cells serve to “soothe” inflammation and thus 
can be considered a special class of effector T cell.  Additionally, effectors are inappropriately 
increased in situations of autoimmunity (Th1 and Th17) and allergies (Th2).  Based on their 
varied functions, it is not surprising that distinct metabolic pathways are also critical for the 
differentiation of specific T cell subsets. Th1, Th2, Th17 primarily utilize glycolysis and 
glutaminolysis for their energy needs and absolutely require GLUT1, while iTregs continue to 
utilize oxidative phosphorylation to meet their energetic needs and are unaffected by GLUT1 
deficiency (16,17).  Instead, inhibition of fatty acid catabolism blunts iTreg differentiation, and 
increased AMPK signaling (such as that induced by metformin) serves to increase iTreg 
differentiation (16).  A glycolytic enzyme recently found to be integral to CD4
+
 T cell 
differentiation is pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl CoA, the 
major building block for fatty acid biosynthesis.  Pyruvate dehydrogenase kinase 1 (PDHK1) 
inhibits PDH activity and enhances glycolytic flux. PDHK1 is selectively upregulated in Th17, 
but not in Th1 or iTregs. Inhibition of PDHK1 decreases Th17 differentiation, demonstrating a 
glycolytic dependence for Th17 cells (18).  Besides metabolizing glucose differently, differential 
components of the amino-acid sensing mTOR signaling pathway are specifically required by 
different T cell subsets.  Loss of the entire mTOR complex leads to loss of differentiation into all 
effector lineages except for iTreg, whose differentiation remains unaffected.  This underscores 
the iTreg reliance on AMPK signaling, which normally serves to inhibit mTOR activity (19).  
mTOR is composed of two different complexes (mTORC1 and mTORC2), each with its own 
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distinct regulation and function (20).  Interestingly, mTORC1 and Rheb, the GTP-binding 
protein that activates mTORC1, are required for Th1 and Th17 differentiation, while mTORC2 is 
needed for Th2 differentiation (21).  T cell effectors also have a differential requirement for fatty 
acid metabolic pathways.  Specifically, Th17 cells require acetyl CoA carboxylase (ACC1), the 
rate-limiting enzyme in fatty acid synthesis, while iTreg differentiation is unaffected by ACC1 
knockout (22).  Further demonstrating a necessity for fatty acid anabolism versus catabolism in 
iTregs, ACC1 is upregulated in obese mice and human memory CD4
+
 T cells.  The enzyme also 
provides fatty acid ligands that enhance retinoic acid receptor-related orphan receptor t isoform 
(RORγt), the lineage-defining, “master” transcription factor for Th17 cells, critical for their 
activity and IL-17 production (23).  Increased ACC1 activity also increases substrates for 
cholesterol metabolism.  Specific oxysterols derived from cholesterol metabolism are potent 
activating ligands for RORγt, increasing RORγt transcriptional activity, and thus Th17 
differentiation (24,25).   
In addition to intrinsic metabolic pathways, various extrinsic metabolic and environmental 
signals heavily influence CD4
+
 T cell differentiation, particularly along the Th17 and iTreg axis.  
As an example, sites of inflammation are frequently hypoxic.  Accordingly, hypoxia inducible 
factor-1α (HIF-1α) has been demonstrated to be essential in upregulating glycolytic genes in 
Th17 cells (26).  HIF-1α also directly enhances transcription of RORγt, while actively targeting 
forkhead box P3 (Foxp3), the iTreg master transcription factor, for ubiquitin-mediated 
degradation (27).  Hormones also exogenously regulate CD4
+
 T cell differentiation.  Many 
autoimmune diseases exhibit sexual dimorphism with increased incidence in females.  
Androgens act as ligands for different peroxisome proliferator activated receptor (PPAR) types.  
In human CD4
+
 T cells, androgens upregulate PPARα which suppresses Th1 and interferon-γ 
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(IFNγ) production, while selectively enhancing IL-17 secretion (28).  Human male CD4
+
 T cells 
with PPARα knockout secreted IFNγ similarly to female CD4
+
 T cells (28).  Other hormonal 
influences on T cell differentiation include leptin, a hormone released to indicate satiety.  Leptin 
signals through signal transducer and activator of transcription 3 (STAT3), which is the major 
STAT required for enhancing RORγt and IL-17 transcription in Th17 cells.  Fittingly, leptin 
receptor expression is required for Th17 differentiation (29) and is yet another signaling pathway 
found to upregulate glycolytic metabolism via HIF-1α (30).   
On the stranger, yet fascinating side, disrupted circadian rhythms have been shown to increase 
Th17 differentiation (31).  Clock proteins rhythmically inhibit NFIL3 (nuclear factor, IL-3 
regulated) expression, which ordinarily represses RORγt transcription.  However, when mice are 
subjected to altered light/dark cycles to mimic jet lag, increased inhibition of NFIL3 by the Rev-
erbα clock protein results in increased Th17 differentiation (31).  Finally, modestly elevated 
NaCl concentrations induce activity of serum glucocorticoid kinase 1 (SGK1), which stabilizes 
IL-23 receptor expression, important for locking in a pathogenic Th17 phenotype (32,33).  
Knockout of SGK1 results in decreased Th1- and Th17-driven autoimmune inflammation in a 
mouse model of multiple sclerosis (EAE, experimental autoimmune encephalomyelitis) due to a 
loss of Th17 stability. This effect was completely reversed by feeding the mice a high-salt diet 
(32,33).  Recently, SGK1 regulation of the Th1 vs Th2 axis was clarified (34).  Activation of 
SGK1 occurs downstream of mTORC2, which is required for Th2 differentiation (21).  
Accordingly, knockout of SGK1 ameliorated Th2-mediated allergic lung inflammation, 
suggesting importance of Th2 rather than Th1 differentiation (34). 
Finally, bacterial metabolic by-products unique to the gut can regulate CD4
+
 T cell 
differentiation. The gut is considered a distinct immunological site due to the constant presence 
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of commensal and potentially pathogenic bacteria, which the immune system must carefully 
discriminate between to appropriately balance inflammation and tolerance.  Proper balance of the 
Th17 versus iTreg axis is of particular importance in the gut, and thus much research has gone 
into exploring mechanisms regulating this balance.  Specific strains of bacteria, the segmented 
filamentous bacteria, are required to induce gut resident Th17 cells (35).  Fatty acids derived 
from the microbiota critically regulate the balance of iTreg and Th17 in the gut.  Short chain 
fatty acids, such as butyrate, induce iTregs, while long chain fatty acids induce Th1 and/or Th17 
differentiation sufficient to enhance autoimmune EAE (36).  Additionally, tryptophan derivatives 
derived from gut bacteria promote iTreg differentiation and quell EAE autoimmune 
inflammation (37).   
O-GlcNAcylation is required for T cell activation 
 
A less well known, yet critical metabolic pathway is the hexosamine biosynthetic pathway 
(HBP).  Incorporating metabolites from carbohydrate, amino acid, fatty acid, and nucleic acid 
pathways, the HBP results in the synthesis of UDP-GlcNAc, the substrate used by O-GlcNAc 
transferase (OGT) to O-GlcNAcylate proteins.  As the concentration of UDP-GlcNAc rises, 
more substrate is available and O-GlcNAcylation increases (38).  Glutamine is a substrate 
required by GFAT (glucose:fructose-6-phosphate amidotransferase), the rate-limiting enzyme in 
the HBP.  Thus, when glucose and glutamine influx rapidly increase during T cell activation, 
UDP-GlcNAc levels and subsequent O-GlcNAcylation can also increase (39).  This effect was 
first observed during the initial identification of intracellular glycosylation with O-GlcNAc in 
activated Jurkat T cells (40).  T cell activation rapidly induced distinct changes in the population 
of O-GlcNAcylated nuclear and cytoplasmic proteins.  O-GlcNAcylation is essential during T 
cell activation, since  siRNA knock-down of OGT significantly hinders T cell activation (2).  
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This effect is due in part because O-GlcNAcylation of NF-κB and NFAT, transcription factors 
essential for IL-2 gene transcription that drive the proliferative response, is required for their 
translocation from the cytoplasm to the nucleus (2,41).  Interestingly, O-GlcNAcylation of NF-
κB was induced under specific conditions such as hyperglycemia, suggesting a link between 
increased O-GlcNAcylation and exaggerated production of inflammatory cytokines such as IFNγ 
under its transcriptional control (41).  O-GlcNAcylation is required during activation in primary 
human T cells as well (3).  A specific requirement for OGT but not OGA function was identified, 
which was linked to OGT localization to a cluster of kinases immediately downstream of TCR 
signaling (3).  This study also identified several new O-GlcNAcylated proteins among these 
proximal kinases, such as LCK and ZAP-70, which are key players in transmitting the TCR 
signal (3).  Identification of OGT-mediated modification of proteins at the beginning of the TCR 
signaling pathway provides a possible explanation for why O-GlcNAcylation levels rise so 
rapidly after activation before nutrient transporters have had a chance to demonstrably increase 
nutrient flux.  Taken together, the data strongly support O-GlcNAc as a critical regulator of 
activation signals needed for T cell proliferation. 
O-GlcNAc in T cell mediated diseases 
 
The role of O-GlcNAc in CD4
+
 T cell differentiation is poorly understood, but several studies 
hint at a role for this modification in regulating T cell effectors in autoimmune diseases.  The X-
linked OGT gene is hypomethylated in T cells from female patients with systemic lupus 
erythematosus, an autoimmune disease with a high prevalence especially in females, mediated in 
part by Th1 and Th17 cells (4).  Additionally, miRNA15-b targeting of OGT transcripts was 
recently found to be down-regulated in T cells from multiple sclerosis patients, resulting in 
increased Th17 differentiation (5).  ELF-1, a transcription factor for the TCR ζ chain gene, 
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requires O-GlcNAcylation and phosphorylation to translocate from the cytoplasm to the nucleus.  
Decreased O-GlcNAcylation was found on ELF-1 in SLE patients and led to a decrease in TCR ζ 
chain levels on their T cells (42,43).  Interestingly, restoring appropriate levels of TCR ζ chain 
was sufficient to ameliorate T effector cell dysfunction (44). These observations suggest 
dysregulated O-GlcNAcylation results in aberrant CD4
+
 T cell effector function.  In particular, 
dysregulated cycling of O-GlcNAc due to changes in OGT levels may have a role in enhancing 
pro-inflammatory T effector function in the context of autoimmunity.  Finally, O-GlcNAcylation 
is essential for T cell malignancy, since T cell-specific OGT knockout prevented malignant 
transformation of PTEN-knockout thymocytes (39).  However, this is likely due more to O-
GlcNAc’s essential role in organizing the mitotic spindle and regulating cellular division than in 
regulating T cell cancers specifically (45-47).  Many unanswered questions remain in our 
understanding of how O-GlcNAc regulates CD4
+
 T cell differentiation and how aberrant O-










CHAPTER 2: METHODOLOGY 
Mouse T cell isolation, activation, and differentiation  
 
C57BL/6 male (Western diet experiments) and female mice (Jackson Laboratories) between 6-24 
weeks of age were used in these studies.  Mice were humanely euthanized using CO2 
asphyxiation according to an Institutional Animal Care and Use Committee (IACUC) approved 
protocol. CD4+ T cells were isolated from spleen using the CD4+ T cell isolation kit (Stem Cell 
Technologies).  CD4+ T cells alone or naïve cells obtained by staining with APC-CD62L and 
FITC-CD44 (BD Biosciences) were sorted and treated with 10 μM Thiamet-G (SD 
Chemmolecules, LLC) or vehicle control for 6 hours.  Cells (2.5 x 10
5
 cells/well) were then 
activated on anti-CD3 and anti-CD28 (Bio X Cell) antibody coated plates.  Plates were prepared 
by addition of 2 μg anti-CD3 and 1 μg anti-CD28 per well of a 48-well plate in PBS containing 
calcium and magnesium incubated overnight at 4°C. At the time of activation, polarizing 
cytokines were added to cells to promote differentiation towards specific lineages as follows: 
Th0 – no cytokines added; Th17– mouse IL-6 (20 ng/mL, Miltenyi), human TGFβ1 (2 ng/mL, 
Miltenyi), anti-IL-4 (10 μg/mL), anti-IFNγ (10 μg/mL).  All cells were incubated at 37 °C in 5% 
CO2 in a 95% humidified incubator. On the second day of culture, mouse IL-2 (eBioscience) at 
20 ng/mL was added to cultures and the cells were re-suspended.  On the fourth day of culture, 
cells were re-suspended, any dead cells were removed by gradient centrifugation with 
Lymphocyte Separation Medium (Corning), and counted with a hemocytometer.  2.5 x 10
5
 cells 
per well were then re-stimulated on plates containing 3 μg anti-CD3 and 1 μg anti-CD28 per 
well, which were prepared as previously described.  24 hours after re-stimulation supernatants 
and cells were harvested.  Mouse IL-17A, IFNγ, IL-4, or IL-10 levels in the supernatants were 
quantified using the cytokine’s corresponding ELISA kit (eBioscience).   
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Western Diet Mouse Model 
 
For Western diet studies, 6-8 week old male C57BL/6 mice (Jackson Laboratories) were fed a 
42% kcal from fat (>60% saturated fat), 0.2% cholesterol, and high sucrose “Western diet” 
(Teklad TD.88137) for 16 weeks.  Control 6-8 week old male C57BL/6 mice were fed standard 
chow, containing 14% kcal from fat (Teklad 8604).  Mice were weighed at 0, 2, 4, 6, 8, 10, 12, 
14, and 16 weeks.  At 15 weeks, control and Western diet fed mice were fasted overnight for 15 
hours.  At the end of the fast, tail vein blood was used to determine the blood glucose level 
(mg/dL) using One Touch Ultra Blue test strips and the One Touch UltraMini blood glucose 
monitoring system (LifeScan).  At 16 weeks mice were sacrificed following a 15 hour overnight 
fast, and splenic CD4+ T cells were used for subsequent studies as described. 
Intracellular Cytokine Staining 
 
CD4+ T cells were isolated and cultured as previously described.  After four days of culture, 
cells were re-suspended, any dead cells were removed by gradient centrifugation with 
Lymphocyte Separation Medium (Corning), and viable cells were re-suspended at a 
concentration of 1-10 million cells per mL.  Cells were stimulated with 50 ng/mL PMA (phorbol 
12-myristate 13-acetate) and 1 μg/mL ionomycin (both Sigma) for 5 hours.  Protein secretion 
was inhibited by addition of 4 μL of BD GolgiStop
TM
 Protein Transport Inhibitor (containing 
monensin) per 6 mL of culture.  After stimulation, cells were washed twice with PBS + 2% FBS 
and counted.  One million cells per condition were added to an Eppendorf tube, spun, and re-
suspended in cold BD Cytofix
TM
 buffer from the Mouse Th1/Th17 Phenotyping Kit (BD 
Biosciences) and incubated for 20 minutes at room temperature.  Cells were then washed twice 
with PBS + 2% FBS and diluted in BD Perm/Wash Buffer
TM
 for 15 minutes at room 
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temperature.  Cells were centrifuged and then re-suspended in 50 μL BD Perm/Wash Buffer
TM
 
plus 20 μL/tube of staining cocktail (mouse PerCP-Cy5.5-CD4, PE-IL-17A, FITC-IFNγ) or BD 
Perm/Wash Buffer
TM
 as a negative control for 30 minutes at room temperature.  Cells were 
washed twice with PBS + 2% FBS and data was acquired on an LSR II (BD Biosciences) and 
analyzed with FlowJo (Tree Star). 
Quantitative Real Time Polymerase Chain Reaction (qPCR) 
 
Mouse or human RNA was extracted by dissolving 2 x 10
6
 cells in TRI reagent (Sigma) followed 
by the addition of chloroform.  The mixture was mixed by inversion, centrifuged, and the 
aqueous layer was taken.  Isopropanol was added to the aqueous layer to precipitate the RNA. 
The RNA was pelleted by centrifugation, washed with 75% ethanol, and allowed to air-dry 
before adding DEPC-treated, RNase free water (Ambion).  RNA of high purity (260/280 and 
260/230 greater than 1.7) was used for further analysis.  0.5-0.75 μg RNA was converted to 
cDNA using iScript reverse transcriptase reaction mix (Biorad) in a thermal cycler (Model 2720, 
Applied Biosystems) using the following protocol: priming, 5 min at 25 °C; RT, 30 min at 42 °C; 
and RT inactivation, 5 min at 85 °C.  For qPCR reactions, 10 μL SsoAdvanced Universal SYBR 
Green Supermix (Biorad), 10-100 ng of cDNA, 0.2 μL each of forward and reverse primers (100 
μM stock concentration), and water to a final reaction volume of 20 μL were added per well to 
96 well-plates (Midsci).  The reactions were run on a CFX96 Real Time PCR Detection System 
(Biorad), using the following conditions: polymerase activation and DNA denaturation, 30 s at 
95 °C; amplification denaturation, 5 s at 95 °C; and amplification annealing and extension, 30 s 
at 60 °C or 62 °C for 40 cycles.  The dynamic range of reverse transcription and the 
amplification efficiency was determined for each primer pair and cell culture condition.  Thus, 
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Cq values within these ranges were reliably used to calculate the fold change in gene expression 





Cells were lysed on ice in 20 mM Tris, pH 7.4, 150 mM NaCl, 40 mM GlcNAc, 2 mM EDTA, 1 
mM DTT, 1% Nonidet P-40 lysis buffer with protease inhibitors (1 mM β-glycerophosphate, 1 
mM NaF, 2 mM PMSF, 1X inhibitor cocktail composed of 1 μg/ml leupeptin, 1 μg/ml antipain, 
10 μg/ml benzamidine, and 0.1% aprotinin (Sigma)) added immediately before lysis.  Lysates 
were incubated on ice for 20 minutes and vortexed every 5 minutes.  Lysates were then 
centrifuged for 20 minutes, 4°C and the supernatant was removed to another tube.  Protein 
concentration of the lysate was determined using protein assay dye reagent (Biorad), using 
known concentrations of bovine serum albumin (Biorad) as the standard.  Lysates were then 
denatured by addition of 4X protein solubility mixture (100 mM Tris, pH 6.8, 10 mM EDTA, 8% 
SDS, 50% sucrose, 5% beta-mercaptoethanol, 0.08% Pyronin Y) and boiling for 2 minutes.  
Equal amounts of lysates were loaded onto 4-15% Criterion precast TGX gels (Biorad). 
Electrophoresis occurred at 125V, and then the gel proteins were transferred to PVDF 
membranes at 0.4A.  Membranes were blocked with 3% BSA, 0.01% sodium azide in TBST (25 
mM Tris,pH 7.6, 150 mM NaCl, 0.05% Tween-20) for at least 20 minutes.  Blots were then 
probed overnight at 4°C with primary antibody to protein of interest at 1:1,000 dilution.  The 
next day blots were washed 5 times in TBST for 5 minutes each.  HRP-conjugated secondary 
antibody at 1:10,000 dilution was added for an hour at room temperature, followed by washing 5 
times for 5 minutes each.  Blots were then developed using the chemiluminescence HRP 
(horseradish peroxidase) antibody detection method (HyGlo Spray, Denville Scientific).  
Commonly, blots were stripped with 200 mM glycine, pH 2.5 for one hour at room temperature, 
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blocked, and re-probed with antibodies to other proteins of interest. Where shown, Image J (48) 
was used to quantify the density of protein bands compared to an internal standard protein band 
such as actin.  Antibodies used in these studies: pACC1 (Ser79), ACC1, pSTAT3 (Tyr705), 
STAT3 (Cell Signaling Technologies); O-GlcNAc (clone: RL2), RORγt (Abcam); actin (Sigma); 
OGT (clone: AL-34) and OGA (clone: 345) antibodies were a generous gift from the laboratory 
of Dr. Gerald Hart in the Department of Biological Chemistry at The Johns Hopkins University. 
Immunoprecipitation (IP) 
 
CD4+ T cells were lysed with lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM DTT, 1% 
NP-40, 40 mM N-acetylglucosamine) and protein concentration was quantified using Protein 
Assay Dye Reagent (Biorad).  One μg of antibody for the protein of interest or one μg of isotype 
matched IgG was added to equal amounts of whole cell lysate diluted to an equal volume in 
Nonidet P-40 lysis buffer and rotated overnight at 4°C.  As an additional control, 1 μg antibody 
to the protein of interest was added to lysis buffer only and rotated overnight at 4°C.  Protein G-
Sepharose beads (Millipore) were added and rotated at 4°C for 2 hours.  The protein G beads 
were then washed three times with NP-40 lysis buffer containing 600 mM NaCl followed by two 
PBS washes, briefly vortexing beads in between washes.  Washed beads were re-suspended in 
Laemlli buffer, boiled for 2 minutes, and run on 4-15% gradient Criterion TGX gels (Biorad).  
Gel proteins were transferred to PVDF membranes and blocked with 3% BSA, 0.01% sodium 
azide in TBST (25 mM Tris,pH 7.6, 150 mM NaCl, 1% Tween-20).  Blots were then probed 
overnight at 4°C with antibodies to O-GlcNAc (RL2, Abcam), followed by immunoprecipitated 
protein (ACC1, pSTAT3 (Tyr705), STAT3 (CST), RORγt (Abcam)) and developed using the 
chemiluminescence HRP (horseradish peroxidase) antibody detection method (HyGlo Spray, 
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Denville Scientific).  For RORγt immunoprecipitation, samples were treated with 5 units of IdeZ 
protease (Promega) in PBS for 30 minutes at 37°C after washing the beads.  
Chromatin Immunoprecipitation (ChIP) 
 
Mouse naïve CD4+ T cells were isolated as previously described from mice fed standard chow.  
TMG was added to naïve CD4+ T cells for 6 hours before activation and differentiated towards 
the Th17 lineage as previously described. After 4 days of culture, cells were harvested and fixed 
with 2 mM ethylene glycol bis(succinimidyl succinate) (EGS; Thermo Scientific)  in PBS for 30 
minutes followed by 1% formaldehyde (Thermo Scientific) for 10 minutes.  Nuclei were 
extracted by re-suspending fixed cells in hypotonic cell lysis buffer (10 mM Tris, pH 8.0, 10 mM 
NaCl, 3 mM MgCl2, 40 mM GlcNAc, 0.5% NP-40) with freshly added protease inhibitors (1 
mM β-glycerophoshate, 1 mM NaF, 1X protease inhibitor cocktail (containing aprotinin, 
leupeptin, antipain, benzamidine), and 2 mM PMSF) for 20 minutes on ice.  Nuclear lysis buffer 
(50 mM Tris, pH 8.0, 10 mM EDTA, 1% SDS, 25% glycerol) with freshly added protease 
inhibitors as previously described and the chromatin was sonicated using the QSonica sonicator 
and cooling system (Model #:Q800R and Oasis 180 respectively) for 200 cycles of 15 seconds 
on at 75% amplitude and 45 seconds off.  Sonication efficiency was checked by treating sheared 
chromatin diluted in ChIP buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-
40, 1% Triton X-100) with 1 μg RNase A (Invitrogen) overnight at 65°C, followed by 2 ug 
Proteinase K (Sigma) for 6 hours at 65°C, before  addition of phenol:chloroform:isoamyl alcohol 
(Acros Organics).  The top aqueous layer was taken and 20 μg of glycogen (Invitrogen) followed 
by 1 mL of cold 100% ethanol (Sigma) was added and incubated overnight at -20°C to 
precipitate the DNA.  The DNA was pelleted by centrifuging for 30 minutes at 4°C, then washed 
with 75% ethanol, and centrifuged for an additional 10 minutes at 4°C.  The supernatant was 
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aspirated and the DNA pellet was allowed to dry for at least 6 hours.  DNA was re-suspended in 
DEPC-treated, DNase free water (Ambion) and run on a 1.5% agarose gel. Bands of 100-300 
base pairs in length indicated a successful sonication cycle.  After ensuring adequate shearing of 
the chromatin, 2 μg of antibody to the protein of interest or 2 ug of isotype control was then 
added to equal amounts of sheared chromatin diluted four-fold with ChIP buffer and rotated 
overnight at 4°C.  The next day 20 μL of isotype matched Dynabeads (Life Technologies) were 
added and rotated for another 2 hours.  Beads were then washed with 1 mL cold ChIP buffer five 
times using the DynaMag-2 Magnet (12321D, Invitrogen), rotating for 5 minutes at 4°C between 
washes.  100 μL of 10% Chelex 100 slurry was added to the beads and boiled for 10 minutes.  1 
μg of RNase A was added and incubated at 65°C for 15 minutes minimum followed by addition 
of 2 μg Proteinase K for 30 minutes at 65°C.  The samples were boiled again for 10 minutes to 
inactivate Proteinase K, and then centrifuged at 12,000 x g for one minute, 4°C. The supernatant 
(70 μL) was transferred to a new tube and the remaining Chelex resin was washed with 130 μL 
water, re-spun, and resulting supernatant added to the first one. 10% of the chromatin used for 
the IP was reserved as input for the qPCR reaction.  DNA from inputs was extracted using the 
same method to determine sonication efficiency.  10 μL of the immunoprecipitated DNA or 
DNA purified from inputs was used per reaction for quantitative PCR and run on the CFX96 
Real Time PCR Detection System as previously described.  The Cq values were normalized to 
percentage of input.  Antibodies used in these studies: rabbit control IgG and RORγt (Abcam) 
Lipidomics 
 
Mouse naïve CD4+ T cells were isolated, activated, and differentiated towards the Th17 lineage 
as previously described from mice fed standard chow with and without TMG treatment.  After 
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four days of culture, cells were re-stimulated with plate-bound anti-CD3 and anti-CD28 for 8 
hours before harvesting, washing with PBS, and snap-freezing the cell pellet. 
Lipid extraction. Frozen cell pellets were subjected to monophasic lipid extraction in methanol : 
chloroform : water (2 : 1 : 0.74, v : v : v) as previously described (49). During lipid extraction, 
each sample was spiked with synthetic di-myristoyl phosphatidylcholine obtained from Avanti 
Polar Lipids (Alabaster, AL), and D7-cholesterol obtained from Steraloids (Newport, RI) at 1 
nmole/mg protein as an internal standard for relative quantitation of lipids and sterols. Dried 
lipid extracts were washed three times with 10 mM ammonium bicarbonate, dried under vacuum, 
and resuspended in methanol containing 0.01% butylated hydroxytoluene. Samples were stored 
under a blanket of nitrogen at -80 degrees Celsius until further analysis. 
Global Lipidomics Analysis. For each analysis, lipid extracts were transferred to an Eppendorf 
twin-tec 96-well plate (Sigma Aldrich, St. Louis, MO), and evaporated under nitrogen. The dried 
lipid film was then resuspended in isopropanol:methanol:chloroform (4:2:1 v:v:v) containing 20 
mM ammonium formate and sealed with Teflon Ultra Thin Sealing Tape (Analytical Sales and 
Services, Pompton Plains, NJ). Appropriate sample dilution to minimize ion suppression effects 
was determined as previously described (49). Global lipidomics analysis was performed by 
direct infusion high resolution/accurate mass spectrometry and tandem mass spectrometry. 
Samples were introduced to the mass spectrometer by nanoelectrospray ionization (nESI) using 
an Advion Triversa Nanomate nESI source (Advion, Ithaca, NY) with a spray voltage of 1.4 kV 
and a gas pressure of 0.3 psi. A Thermo Scientific LTQ-Orbitrap Velos (San Jose, CA) mass 
spectrometer was used for lipid detection. High resolution MS and MS/MS spectra were acquired 
for each sample in positive and negative ionization modes using the Orbitrap FT analyzer 
operating at 100,000 mass resolving power (defined at m/z 400).  
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Analysis of Free and Total Sterol Content. Sterols and oxysterols were analyzed by high 
resolution/accurate mass LC-MS using a Shimadzu Prominence HPLC equipped with an in-line 
solvent degassing unit, autosampler, column oven, and two LC-20AD pumps, coupled to a 
Thermo Scientific LTQ-Orbitrap Velos mass spectrometer. Lipid extracts were used directly for 
analysis of ‘free’ sterols, or subjected to alkaline hydrolysis of sterol esters for analysis of total 
cellular sterols as previously described (50). Ten microliter injections of each total or hydrolyzed 
lipid extract were separated using a Phenomenex (Torrance, CA) Synergi Hydro-RP C18 
column, 2 mm x 150mm, with 3 micron particles and 80 micron pore size, at 50 degrees Celsius. 
The gradient elution method was modified from (50) and utilized A: water containing 0.1% 
formic acid and B: methanol containing 0.1% formic acid, with a 13 minute gradient from 85% 
B to 100% B at a flow rate of 250 microliters/minute. The column eluent was introduced to the 
LTQ-Orbitrap Velos by a heated electrospray ionization source, using a spray voltage of 4.5 kV, 
sheath gas pressure of 30 psi, and auxillary gas pressure of 10 psi. The source heater and MS 
capillary inlet tube were held at 350 degrees Celsius. Sterols and oxysterols were analyzed by 
full scan positive ion mode MS using the Orbitrap detector at a resolution of 60,000 (defined at 





which were the most abundant sterol ions formed under the conditions utilized. Targeted high 
resolution HCD-MS/MS at 45% normalized collision energy was employed on known sterol-
related ions and their product ions (50) to verify the identity of each sterol peak. 
Peak finding, analyte identification, and quantification. For global lipidomics analysis, lipids 
were identified using the Lipid Mass Spectrum Analysis (LIMSA) v.1.0 software linear fit 
algorithm, in conjunction with a user-defined database of hypothetical lipid compounds for 
automated peak finding and correction of 
13
C isotope effects. Relative quantification of lipid 
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abundance between samples was performed by normalization of target lipid ion peak areas to the 
di-myristoyl phosphatidylcholine internal standard as previously described (51).  For free and 
total sterol analysis, chromatographic peak alignment, compound identification, and relative 




Mouse naïve CD4+ T cells were isolated, activated, and differentiated towards the Th17 lineage 
as previously described from mice fed standard chow.  After 4 days of culture, cells were 
harvested, lysed, and ACC1 was immunoprecipitated as previously described.  Immune-purified 
complexes bound to agarose beads were trypsin-digested as previously described (53). 
LC-MS analysis. Following enzymatic digestion, the resulting peptides were concentrated on a 
centrivac concentrator (Labconco) to a final volume of 20 µL. The peptide extracts were 
analyzed using an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) coupled 
to an uHPLC (nLC 1200, Thermo Fisher Scientific). In each run, the sample was injected 
directly into the reversed phase column (Acclaim PepMap RSLC, 50 μm x 15 cm, C18 reversed 
phase  2 μm, 100Å), and washed with 0.1% formic acid for 5 minutes at 500 nl/min. The column 
was mounted on the electrospray stage of the mass spectrometer, and the peptides were eluted 
with a gradient of acetonitrile (solvent B: 90 % acetonitrile, 0.1% formic acid) in 0.1% formic 
acid in water (solvent A). The gradient profile was as follows:  0-5 min, 5-15% B; 5-60 min, 15-
40% B; 60-70 min, 40% B; 70-75 min, 40-75% B; 75-83 min 75% B. At the end of each 
chromatographic run, the column was washed with 100% B. The flow rate was maintained at 
300 nl/min. 
21 
MS Acquisition. The mass spectrometer was operated in positive ionization mode with a 
nanospray flex ionization source operated at 2.6 Kv and source temperature at 250.  Multiple 
runs were performed using different fragmentation methods as described below. The instrument 
was operated in data-dependent acquisition mode, with full MS scans over a mass range 
of m/z 350–1900 with detection in the Orbitrap (120 K resolution) and with auto gain control 
(AGC) set to 100,000.  In each cycle of data-dependent acquisition analysis, following each 
survey scan, the most intense ions above a threshold ion count of 30,000 were selected for 
fragmentation at normalized collision energy of 28% (HCD) or 35% (CID). The number of 
selected precursor ions for fragmentation was determined by the “Top Speed” acquisition 
algorithm and a dynamic exclusion of 60 s. Fragment ion spectra were acquired in the linear IT, 
with an AGC of 4,000 and a maximum injection time of 300 ms for IT MS2 detection.  For ETD 
fragmentation, calibrated charge dependent ETD parameters were enabled to determine ETD 
reagent ion AGC and ETD reaction times, and all MS/MS were mass analyzed in the Orbitrap 
with a resolution of 15,000 K at 200 m/z. All data were acquired with Xcalibur software v3.0.63 
(Tune v2.0 1258). 
Data analysis. For data analysis all MS/MS scans were searched using Proteome Discoverer 
(version 2.2, Thermo Fisher Scientific) running the Sequest HT algorithm.  A database search 
was conducted against a human protein database derived from the NIBInr repository as in 
January 9, 2017. The refined data were subjected to database search using trypsin cleavage 
specificity, with a maximum of 2 missed cleavages. The following variable modifications were 
selected: pyroglutamination from Q and E (N-terminal), oxidation of M, and deamidation of N, 
Q. Carboxymethylation of C was selected as a fixed modification. HexNac was selected as 
variable modification. A maximum of 3 modifications/peptide was allowed.  Estimation of false 
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positive rate (FDR) was conducted by searching all spectra against a decoy database consisting 
of the inverted sequences of all proteins in the original (direct) database. For peptide 
identification a FDR £ 1 was defined and a minimum of two unique peptides per protein was 
required for protein identification. Amino acid sequence assignment of all peptides of interest 
was subsequently inspected manually. 
Human T cell isolation, activation, and differentiation 
 
Human whole blood samples were obtained with consent from patient volunteers by the 
Biospecimen Repository Core Facility (BRCF) at the University of Kansas Medical Center.  
Inclusion criteria for volunteers was a body mass index (BMI, calculated as weight in 
kilograms/height in meters squared) between 18-30 and no prior type 1 or type 2 diabetes 
diagnoses.  Exclusion criteria for samples included patient history of or current immunotherapy 
for cancer, autoimmune disorder, or current use of steroids or immune-modifying drugs (i.e. 
methotrexate).  Whole blood was diluted 1:1 with PBS and gently layered on top of Lymphocyte 
Separation Medium (Corning) and then centrifuged at 2,000 x g for 15 minutes at room 
temperature with the lowest level of brake.  Samples of plasma were collected and snap frozen, 
and the remaining plasma was aspirated.  The white blood cell layer was collected and washed 
twice with PBS. CD4+ T cells were isolated from the washed white blood cell layer using anti-
human CD4 particles (BD Biosciences).  Naïve CD4+ T cells were obtained by staining CD4+ 
cells with mouse anti-human CD45RA and mouse anti-human CD197 (CCR7) (BD Biosciences) 
for 30 minutes on ice, washing with PBS + 2% FBS, and then sorting for the double-positive 
population of cells.  Unsorted CD4+ T cells and naïve cells were treated with TMG or vehicle for 
6 hours before activation with anti-CD3 and anti-CD28 conjugated beads from the Human T Cell 
Activation/Expansion Kit (Miltenyi). Cells were cultured in RPMI-1640 media (Sigma) 
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containing 10% FBS (Gemini), 1% penicillin-streptomycin (Life Technologies), 2 mM 
GlutaMAX (Life Technologies), 10 mM HEPES, 1 mM sodium pyruvate, and 1 mM MEM non-
essential amino acids (Sigma).  Unsorted CD4+ T cells and naïve CD4+ T cells were cultured 
under both Th0 (no polarizing cytokines added) or Th17 conditions (human IL-6 (50 ng/mL), 
human IL-1β (10 ng/mL), human IL-23 (10 ng/mL), human TGFβ1 (3 ng/mL) (all Miltenyi), and 
neutralizing antibodies to IFNγ (clone: XMG1.2) and IL-4 (clone: 11B11) at 10 μg/ml (Bio X 
Cell)).  All cells were incubated at 37 °C in 5% CO2 in a 95% humidified incubator. On day 3 of 
culture, 20 ng/mL of human IL-2 (Miltenyi) was added to cells per the expansion kit protocol. 
On day 7 of culture, cells and supernatants were harvested.  IL-17A levels in supernatants were 
quantified using a human IL-17A ELISA (Invitrogen) and normalized to number of cells present 
at day 7.  Protein and RNA was harvested from cells and used for western blotting or qPCR 
analyses respectively as previously described.   
Statistics 
 
Student’s T test was performed to compare means between two groups.  A p value less than 0.05 
was considered statistically significant (*), less than 0.01 (**), and less than 0.001 (***).   





 Forward (5’3’) Reverse (5’3’) 
HPRT GGCCAGACTTTGTTGGATTTG CGCTCATCTTAGGCTTTGTATTTG 
24 
IL-17A CGCAATGAAGACCCTGATAGAT CTCTTGCTGGATGAGAACAGAA 
IL-23R GAGCCAGACAGCAAGTATGT CAGTTTCTTGGGAAGTTTGGTG 
IFNγ GGCCATCAGCAACAACATAAG GTTGACCTCAAACTTGGCAATAC 
IL-4 GAAGAACACCACAGAGAGTGAG TGCAGCTCCATGAGAACAC 
IL-5 CCCAACCTTAGCATCCTTTCT AGGGAGTTGAGGAGAGATTGA 
IL-10 TGCACTACCAAAGCCACAA GATCCTCATGCCAGTCAGTAAG 










 Forward (5’3’) Reverse (5’3’) 
HPRT CTTTCCTTGGTCAGGCAGTATAA AGTCTGGCTTATATCCAACACTTC 
IL-17A ACCGGAATACCAATACCAATCC GGATATCTCTCAGGGTCCTCAT 
IL-23R GCTGGTGTCATGGAGGAATTA TTCCTTGGTTGGCAGTTCTTA 





CHAPTER 3: RESULTS 
In murine CD4+ T cells, pharmacological elevation of O-GlcNAc increases pro-
inflammatory IL-17A and IFNγ cytokines, while having no effect on anti-inflammatory IL-
10 and IL-4 cytokines. 
 
To determine if O-GlcNAc plays a role in the function of T cell effectors, we treated murine 
splenic CD4+ T cells with Thiamet-G (TMG), a highly specific OGA inhibitor (54), for 6 hours 
before activation under non-polarizing conditions (termed Th0).  Six hours allows for total 
cellular level of O-GlcNAc to become prominently increased, and thus will provide information 
on how T cell effector function is altered under abnormally elevated O-GlcNAc levels.  TMG 
treatment led to elevated O-GlcNAc levels over the four days of cell culture (Figure 1A).  As 
has been previously observed (55,56), levels of OGT decrease and levels of OGA increase in 
response to elevated O-GlcNAcylation in an attempt to restore steady state levels of O-GlcNAc.  
This is a well-described compensatory phenomenon, suggesting cells have a particular level of 
O-GlcNAcylation that is ideal for their function.  Interestingly, re-stimulation of CD4+ T cells 
after 4 days of culture appears to “reset” or promote a restoration of the homeostatic level of O-
GlcNAc, OGT, and OGA.  Although the TMG treated cells still had elevated O-GlcNAc levels 
on day 5, the level decreased dramatically, while activation in the untreated cells increased O-
GlcNAc levels—a phenomenon which confirms previous reports (2,57).  These results suggest a 
critical level of O-GlcNAc is essential for T cell activation and demonstrate the effect of TMG 
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After activated CD4+ T cells differentiated and proliferated over the course of four days and 
cells were re-stimulated, supernatants were harvested 24 hours later.  The levels of key cytokines 
 
Figure 1.  In murine CD4+ T cells, pharmacological elevation of O-GlcNAc increases 
pro-inflammatory IL-17A and IFNγ cytokines, while having no effect on anti-
inflammatory IL-10 and IL-4 cytokines. A. TMG treatment increases O-GlcNAc levels 
over the course of CD4+ T cell differentiation and proliferation with corresponding 
decreases in O-GlcNAc transferase (OGT) and increases in O-GlcNAcase (OGA).  The 
red arrow indicates the time of re-stimulation. B. Protein levels of cytokines secreted from 
CD4+ T cells with and without TMG treatment.  C. Transcript levels of cytokines 
secreted from CD4+ T cells with and without TMG treatment. D. Protein level of IL-17A 
in naïve cells treated with and without TMG and polarized to the Th17 lineage.  E. 
Transcript level of IL-17A in naïve cells treated with and without TMG and polarized to 
the Th17 lineage.  F. Representative histogram showing CD4+ IL-17+ cells are 
significantly increased with TMG treatment. 25K cells plotted per condition. Dead cells 
were excluded.  Bars represent mean +/- SEM of 5 biological replicates in B. and C. and 3 






















produced by the four main effector types (Th1, Th2, Th17, and iTreg) were analyzed by ELISA.  
Strikingly, IL-17A, the major cytokine secreted by Th17 cells, doubled (Figure 1B).  
Additionally, IFNγ, the major cytokine secreted by Th1 cells was also significantly increased.  
However, IL-4 and IL-10, cytokines predominantly produced by the Th2 and iTreg lineages 
respectively, showed no significant changes.  Since both IL-17A and IFNγ are pro-inflammatory 
cytokines and IL-4 and IL-10 have immunomodulatory functions, this suggests that elevated O-
GlcNAcylation promotes increased inflammatory function of CD4+ T cells, while having no 
significant effect on the anti-inflammatory function.  Transcript levels of IL-17A, IFNγ, IL-4, 
and IL-10 followed similar trends to protein levels (Figure 1C).  Additionally, another critical 
Th17 marker, IL-23 receptor (IL-23R), was also significantly increased.  IL-23 binding and 
signaling through IL-23R stabilizes the Th17 phenotype (58,59) and is also a marker of 
pathogenic Th17 function (60).  Overall, markers of Th17 function are increased with elevated 
O-GlcNAcylation. 
Th17 cells compose less than 1% of CD4+ T cells in the peripheral blood (61).  To investigate 
the mechanism of O-GlcNAc’s regulation of Th17 function, we sought to obtain a more 





) and then treated with and without TMG before activation and polarization 
towards the Th17 lineage.  Potentially, polarization would overcome the effect of TMG we 
previously observed with a mixed population of CD4+ T cells. However, even with polarization 
towards a Th17 lineage, TMG treatment still significantly increased both protein and transcript 
IL-17A levels (Figure 1D and 1E).  Intracellular cytokine staining showed a significant but 
modest increase in CD4+IL-17+ cells, suggesting there may be some effect on differentiation as 
well as functional cytokine output (Figure 1F). 
A. 
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In human CD4+ T cells, pharmacological elevation of O-GlcNAc increases pro-
inflammatory IL-17A cytokine levels in addition to transcript levels of genes under RORγt 
transcriptional control.  
 
Th17 cells infiltrate adipose tissue to a greater extent in obese humans (62) and secrete more IL-
17A, contributing to adipose insulin resistance (63).  Thus, we wanted to determine if TMG 
treatment increased IL-17A from human CD4+ T cells.  We obtained fresh venous whole blood 
from human volunteers through the Biospecimen Repository Core Facility (BRCF) at the 
University of Kansas Medical Center.  Healthy volunteers were defined by a non-obese BMI 
(between 18 and 30 kg/m^2) and no previous type 1 or type 2 diabetes diagnoses.  Volunteers 
were excluded if they had a history of autoimmunity or past or current treatment with immune-
modifying agents (i.e. immunotherapy for cancer treatment).  Further characteristics of 
volunteers, including gender, age, and ethnicity, are detailed in Table 1.   
Table 1.  Human Volunteer Characteristics 
Female (%) 8/9 (88.9) 
White, Non-Hispanic (%) 8/9 (88.9) 
Mean age (range) 53 (34-80) 
Mean BMI (range) 22.6 (18.9-26.4) 
CD4+ T cells were isolated from blood and treated with and without TMG before activation 
under Th0 and Th17 conditions.  IL-17A significantly increased with elevated O-GlcNAc levels 
under both Th0 and Th17 polarizing conditions, recapitulating the results seen in mice (Figure 
2A).  Since Th17 function in human CD4+ T cells was also sensitive to changes in O-GlcNAc, 




) from the blood, treated with and without 
TMG before activation, and polarized towards the Th17 lineage.  Again, increasing O-GlcNAc 
trended towards increased IL-17A secretion from naïve CD4+ T cells polarized to the Th17 
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lineage (Figure 2B).  Next we compared transcript levels of IL-17A and other pro-inflammatory 
cytokine markers, such as IL-23R and IFNγ, with and without TMG treatment in the CD4+ T 
cell population polarized to Th17 lineage.  IL-17A and IL-23R, both transcriptional targets of 
RORγt, and IFNγ, the main pro-inflammatory cytokine from Th1 cells, were significantly 
increased with elevated O-GlcNAcylation (Figure 2C).  Thus, we have demonstrated a clear 
effect of elevated O-GlcNAc levels on regulating pro-inflammatory cytokine signaling—













































TMG -       + -         + -       + 
Figure 2.  In human CD4+ T cells, pharmacological elevation of O-GlcNAc 
increases pro-inflammatory IL-17A cytokine levels in addition to transcript levels 
of genes under RORγt transcriptional control. A. TMG treatment increases IL-17A 
secretion from human CD4+ cells polarized under Th0 and Th17 conditions.  B. TMG 





) CD4+ cells polarized under Th17 conditions.  C. IL-17, IL-23R, 
and IFNγ transcript levels all significantly increase with TMG treatment.  Bars 
represent mean +/- SEM of 9 and 7 human donors in A. and B. respectively and mean 
+/- SEM of 7 human donors in C.; * p < 0.05, **p < 0.01 
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Western diet feeding in mice results in elevated O-GlcNAc levels in naïve CD4+ T cells and 
increases IL-17A secretion from naïve CD4+ T cells, which is exacerbated by TMG 
treatment. 
 
The previous data provide evidence that elevated O-GlcNAc increases pro-inflammatory 
cytokine production from CD4+ T cells.  To investigate the physiological relevance of this effect 
in a disease model, we utilized a diet-induced obese mouse model (DIO).  A DIO model was 
chosen because 1.) IL-17A is increased in the serum of obese mice and humans (64) and 
contributes to chronic low-grade inflammation that drives downstream pathology (65,66), and 2.) 
O-GlcNAc levels are sensitive to the nutritional state of the host and thus we would expect them 
to be elevated in a DIO model, phenocopying the effects of TMG in our in vitro studies.  To test 
this hypothesis, we fed C57BL/6 male mice a high fat and cholesterol “Western” diet (WD) 
chow for 16 weeks.  As expected, WD fed mice gained significantly more weight and their blood 
glucose was significantly elevated 15 weeks after initiation of the diet compared to mice fed 




) isolated from 
WD fed mice had significantly elevated O-GlcNAc levels compared to SC fed mice (Figure 
3C).  Interestingly, OGT and OGA levels were not different between WD and SC fed mice, 
suggesting that elevated O-GlcNAc levels in the WD fed mice reach a new, albeit elevated “set 
point,” where levels of OGT and OGA are not down- or up-regulated respectively to try to 
maintain typically lower homeostatic O-GlcNAc levels.  When naïve CD4+ T cells from WD 
and SC fed mice were activated and polarized towards a Th17 lineage, cells from WD fed mice 
secreted more IL-17A as would be expected from previous studies (64,67).  Strikingly, when the 
same naïve CD4+ T cells from WD and SC fed mice were treated with TMG before activation 
and polarization, cells from SC fed mice secreted levels of IL-17A comparable to cells from WD 
fed mice and IL-17A secretion from cells from WD fed mice was even further exacerbated 
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(Figure 3D).  The trends seen with IL-17A transcript levels were similar to the trends seen in 
protein levels (Figure 3E).  Taken together, these results demonstrate that in a type 2 diabetes 
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pharmacological OGA inhibition by TMG.  This suggests that O-GlcNAc is a critical regulator 
of Th17 functional activity and when aberrantly elevated—as in obesity—could contribute to the 






































Elevated O-GlcNAcylation has no effect on RORγt protein or transcript levels over the 24 
hour period after re-stimulation when increased IL-17 secretion occurs. 
 
To investigate a mechanism for increased IL-17A secretion under OGA inhibition, we 
hypothesized that RORγt (retinoic acid related orphan receptor, t splice variant) would be 
increased with elevated O-GlcNAc levels. RORγt is the master transcription factor that directs 
the Th17 lineage and is essential for IL-17A gene transcription.  Interestingly, in naïve cells 
isolated from wild type mice and polarized to the Th17 lineage, we found no differences in 
RORγt by either protein or transcript level in the presence of TMG on the fourth day of cell 
culture (indicated as “0” time point) or over a 24 hour span after re-stimulation (Figure 4A and 
4B). Furthermore, we saw no significant differences in RORγt protein or transcript levels at 24 
hours after re-stimulation in Th17 differentiated cells from mice fed SC or WD (Figure 4C and 
4D).  These results suggest that O-GlcNAc neither regulates the stability of RORγt or its 
transcripts nor does O-GlcNAc affect transcription factors required for RORγt transcription.   
  
Figure 3.  Western diet feeding in mice results in elevated O-GlcNAc levels in naïve 
CD4+ T cells and increases IL-17A secretion from naïve CD4+ T cells, which is 
exacerbated by TMG treatment. A. WD feeding results in significantly increased 
weight gain.  B. WD feeding results in significantly elevated fasting blood glucose 
levels.  C.  WD fed mice have significantly elevated O-GlcNAc levels.  D.  Naïve CD4+ 
T cells polarized to the Th17 lineage from WD fed mice secrete significantly more IL-
17A than cells from SC mice.  Cells from SC fed mice treated with TMG secrete levels 
similar to cells from WD mice, and TMG treatment of cells from WD fed mice 
significantly exacerbates IL-17A secretion.  E.  IL-17A transcript levels mimic the 
trends seen with IL-17A protein secretion.  In A. and B., points represent average -/+ SD 
and are calculated from 4 and 5 biological replicates (SC and WD respectively).  In C., 
inset of densitometry is from 8 biological replicates and bars represent mean -/+ SD. 
Each lane in blot represents cell lysate from one mouse.  In D. and E. bars represent 
mean -/+ SEM of 4 and 5 biological replicates (SC and WD respectively).  HPRT is used 
an internal reference for gene expression.   
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Elevated O-GlcNAcylation does not increase STAT3 levels or alter activating 
phosphorylation of STAT3.  
A.  
      Th17 – TMG                                    Th17 + TMG 
WB: Actin 
WB: RORγt 
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Another critical transcription factor involved in the initial differentiation of Th17 cells is STAT3 
(signal transducer and activator of transcription 3).  Interleukin-6 (IL-6), an essential cytokine for 
Th17 differentiation, signals through IL-6 receptor, which activates STAT3 through 
C. 
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Figure 4.  In murine differentiated Th17 CD4+ T cells, pharmacological elevation of 
O-GlcNAc does not affect RORγt protein or transcript levels. A. Prior to re-
stimulation on the fourth day of culture and over 24 hours after re-stimulation, RORγt 
protein levels are unchanged.  Densitometry was used to compare RORγt:actin ratio at 
specified time points. Blot is representative of 3 biological replicates. Bars represent the 
mean +/- SEM of 3 biological replicates.   B. Transcript levels of RORγt are unchanged 
24 hours after re-stimulation.  RORγt gene expression was normalized to HPRT 
expression.  Bars represent mean +/- SEM of 5 biological replicates. C.  RORγt protein 
levels are not different between differentiated Th17 cells from SC and WD mice -/+ 
TMG. Each lane represents cell lysate from one mouse.  TMG treated lanes correspond to 
same mouse as untreated lanes. D. RORγt transcript levels are not different between 
differentiated Th17 cells from SC and WD mice -/+ TMG. Bars represent mean +/-SEM 
of 4 biological replicates. 
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phosphorylation at tyrosine 705 (68).  Phospho-STAT3 induces dimerization and translocation to 
the nucleus and binding of the promoters of various genes essential for the Th17 lineage, 
including RORC and Il17a genes coding for RORγt and IL-17A respectively (69).  Previously, 
STAT3 has been identified as being O-GlcNAcylated with the most recent evidence identifying a 
mono-glycosylated form in human T cells (3,70,71).  Since O-GlcNAc and phosphorylation 
influence one another (55), we hypothesized that O-GlcNAc regulates STAT3 in our model by 
enhancing its activating phosphorylation at tyrosine 705, leading to increased IL-17A 
transcription.  In our hands, we were unable to detect O-GlcNAcylation of STAT3 or phospho-
STAT3 by immunoprecipitation in murine naïve cells polarized to the Th17 lineage ex vivo on 
the fourth day of cell culture (represented by 0 time point on the Western blot) or 10 minutes 
after re-stimulation (Figure 5A).  It is possible we were unable to detect O-GlcNAcylation that is 
in fact occurring.  However, we also detected no changes in total cellular level of STAT3 or 
changes in activating phospho-STAT3 with TMG treatment in CD4+ T cells treated with and 
without TMG over the five days of cell culture (Figure 5B).  These results indicate that 
aberrantly elevated O-GlcNAc is not profoundly affecting STAT3 levels or activity and thus 
STAT3 is unlikely to be the transcription factor responsible for the increased IL-17 transcription 
seen with TMG treatment. 
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Elevated O-GlcNAcylation promotes retention of RORγt at the IL-17 locus.  
 
With no apparent effect of elevated O-GlcNAcylation on the levels of two transcription factors 
arguably most essential for IL-17A transcription, we speculated that RORγt is being retained at 
the IL-17A locus—a phenomenon which has been previously observed (23).  We performed 
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Figure 5.  Neither STAT3 nor phospho-STAT3 (Y705) are O-GlcNAcylated and 
the ratio of pSTAT3:STAT3 does not change with TMG treatment over the 
course of differentiation.  A. STAT3 and pSTAT3 (Y705) are not O-GlcNAcylated.  
B. pSTAT3:STAT3 ratio does not change with TMG treatment.  Blots represent at 
least 3 replicates. 
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chromatin immunoprecipitation (ChIP) of RORγt at the IL-17 promoter and an enhancer, 
conserved non-coding sequence 2 (CNS-2), which is required for IL-17A transcription (72).  
TMG treatment resulted in significantly increased RORγt binding at promoter and enhancer 
regions in Th17 cells differentiated ex vivo and fixed on the fourth day of cell culture (Figure 
6A).  O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) are frequently part of 
transcriptional complexes and O-GlcNAc cycling is known to be essential for modulation of the 
activity of many transcription factors (73-77).  Potentially, OGT could be O-GlcNAcylating 
RORγt and directly affecting its activity or stability at the IL-17A locus.  However, we were 
unable to detect O-GlcNAcylation of RORγt by immunoprecipitation (Figure 6B).  Thus, TMG 
treatment appears to promote “locking in” of RORγt at the IL-17A promoter and enhancer 
regions.   
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In murine differentiated Th17 cells, pharmacological elevation of O-GlcNAc increases lipid 
ligands capable of increasing RORγt transcriptional activity.  
 
Among the lineage defining transcription factors for CD4+ T cells, RORγt activity is uniquely 
regulated by the binding of lipid ligands.  We thus investigated alterations in the lipidome that 
might increase RORγt transcriptional activity at the IL-17 gene.  Cholesterol biosynthetic 
intermediates, such as 7β, 27-dihydroxycholesterol (7β, 27-OHC) and 7α, 27-
dihydroxycholesterol (7α, 27-OHC), are known endogenous ligands capable of binding the 
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Figure 6.  Elevated O-GlcNAcylation promotes retention of RORγt at the IL-17 
locus.  A.  RORγt is significantly increased at the IL-17 promoter and CNS2 
enhancer region with TMG treatment on day 4 of cell culture.  Bars represent mean 
+/- SEM of 4 biological replicates. *p < 0.05, **p < 0.01  B. RORγt is not O-
GlcNAcylated in Th17 cells differentiated ex vivo.  IdeZ protease was used to cleave 
antibody at the hinge region and allow visualization of proteins that migrate with 






































ligand binding domain of RORγt, strongly activating its transcriptional activity (24,25).  
Additionally, fatty acids are critical for optimal RORγt activity as evidenced by a lack of Th17 
differentiation under conditions of pharmacological inhibition or genetic deletion of the rate-
limiting enzyme in fatty acid biosynthesis, acetyl CoA carboxylase 1 (ACC1) (22,23).  The type 
of fatty acid ligand is also important for RORγt activity.  An increased ratio of saturated fatty 
acids (SFA) to polyunsaturated fatty acids (PUFA) increases RORγt transcriptional activity at the 
pro-inflammatory IL-17A promoter, while decreasing activity at the anti-inflammatory IL-10 
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alters the lipidome of T cells, we treated murine splenic naïve CD4+ T cells with and without 
TMG before activation, polarized towards a Th17 lineage, and then performed an untargeted 
broad analysis of the lipidome by mass spectrometry.  Of note, cholesterol and total sterol 
populations were significantly elevated with TMG treatment (Figure 7A).  One possibility for 
these results is increased cholesterol synthesis and thus increased cholesterol biosynthetic 
intermediates capable of activating RORγt.  Additionally, of the top twenty fatty acids detected 
in the cells, most SFA, such as stearic acid (C18:0), were significantly increased and all PUFA, 
such as arachidonic acid (C20:4), were significantly decreased with TMG treatment (Figure 7B 
and 7C).  Together, these results demonstrate that elevated O-GlcNAcylation alters the lipid 
microenvironment such that cholesterol intermediates and fatty acids capable of acting as 
activating ligands of RORγt at the IL-17A locus were significantly increased.  Furthermore, an 
increase in these lipid ligands is a possible explanation for why RORγt is retained longer at the 
IL-17 locus.  
44 
TMG treatment changes flux through the interrelated ceramide, sphingomyelin, and 
choline metabolic pathways. 
 
Another striking finding from the lipidomics analysis is a significant increase in ceramide with 
concomitant significant decrease in sphingomyelin levels with TMG treatment (Figure 8A).  
Figure 7.  In murine differentiated Th17 cells, pharmacological elevation of O-
GlcNAc increases lipid ligands capable of increasing RORγt transcriptional activity. 
A. The absolute value or normalized ion abundance of total sterols and particularly 
cholesterol are increased with TMG treatment.  B. Of the top 20 fatty acids present in cells, 
the percentage of saturated fatty acids increased with TMG treatment.  C. Of the top 20 
fatty acids present in cells, the percentage of all polyunsaturated fatty acids decreased with 
TMG treatment.  Bars represent mean +/- SD of 5 biological replicates; * p < 0.05, **p < 
0.01, *** p < 0.001 
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Ceramide and sphingomyelin are interchangeable through the actions of membrane bound 
sphingomyelinase and sphingomyelin synthase.  An increase in ceramide levels is notable 
because ceramide is known to promote insulin resistance in adipose, muscle, and liver and is a 
general cellular metabolite that accumulates in obesity (79).  Ceramide synthase 6 is the 
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Figure 8. TMG treatment changes flux through the interrelated choline, 
sphingomyelin, and ceramide metabolic pathways.  A. PC is significantly 
decreased with TMG treatment, while all other phospholipids significantly increase.  
Percentages are means of 5 biological replicates (all S.D. less than 0.35%) in A. PC = 
phosphatidylcholine, PE = phosphatidylethanolamine, PG = phosphatidylglycerol, PI 
= phosphatidylinositol, PS = phosphoserine. B. The absolute value of ceramide 
significantly increases, while sphingomyelin significantly decreases with TMG 
treatment.  C. Total fatty acid percentage of palmitic acid significantly decreases with 
TMG treatment.  In B. and C., bars represent mean +/- S.D. *p < 0.05, **p < 0.01, 
***p< 0.001 
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ceramide synthase isoform highly expressed in immune cells and preferentially generates 
ceramide with fatty acyl chains composed of palmitic acid (C16:0) (80).  Intriguingly, we found 
that of the saturated fatty acids present in the top twenty fatty acids present overall, only palmitic 
acid (C16:0) was significantly decreased (Figure 8B).  Potentially, elevated O-GlcNAcylation 
alters the metabolism of the T cells such that free palmitic acid is being more rapidly diverted 
into acylation of proteins or formation of other metabolites such as C16-ceramide.  The choline 
metabolic pathway also feeds into pathways that generate sphingomyelin and ceramide.  
Phosphatidylcholine (PC) plus ceramide can be enzymatically converted to sphingomyelin with 
the release of diacylglycerol (PC + ceramide  sphingomyelin + DAG) (81). Interestingly, we 
found a significant decrease in the percentage of phosphatidylcholine with compensatory 
increases in the other 4 phospholipid classes (Figure 8C).  In addition to choline being shunted 
towards PC and sphingomyelin formation, it may also have implications for the methylation 
status of the cell, since choline can also be converted to betaine, which is a metabolite involved 
in the regeneration of methionine from homocysteine (81). Overall, these results suggest aberrant 
O-GlcNAcylation is promoting an “obese,” inflammatory lipid signature in T cells with potential 
cross-talk with methylation via disruptions in choline metabolism. 
Acetyl CoA carboxylase 1 (ACC1), the rate limiting enzyme of fatty acid biosynthesis, is 
modified by O-GlcNAc. 
 
The substrates needed for both long chain fatty acids and cholesterol synthesis originate from the 
actions of acetyl CoA carboxylase (ACC1), the rate-limiting enzyme in fatty acid catabolism.  
ACC1 catalyzes the carboxylation of acetyl CoA to form malonyl CoA.  Importantly, de novo 
fatty acid synthesis is essential for Th17 differentiation (22), and specifically ACC1 activity is 
essential for Th17 differentiation (23).  UDP-GlcNAc, OGT’s substrate, is made through the 
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hexosamine biosynthetic pathway and requires input from all four major biomolecules: 
carbohydrate, amino acid, fatty acid, and nucleic acid (82).  As nutrient flux changes through the 
cell, UDP-GlcNAc concentrations and O-GlcNAcylation by OGT change accordingly (38).  
Thus, we hypothesized that as a cellular nutrient sensor, O-GlcNAc modifies ACC1 and 
regulates its activity.  We first immunoprecipitated ACC1 from CD4+ T cells and observed that 
it was O-GlcNAcylated, and the reverse procedure of pulling proteins down with an O-GlcNAc 
antibody also yielded ACC1 (Figure 7A).  We then confirmed this finding by performing 
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electron transfer dissociation mass spectrometry (ETD-MS) on immunoprecipitated ACC1 from 
TMG treated murine naïve T cells polarized ex vivo to the Th17 lineage.  Mass spectrometry 
analysis uncovered 4 high confidence O-GlcNAc sites on murine ACC1 (Figure 7B, Table 2).  
Two of these sites had homologous sites in a reported human partial C-terminal domain ACC1 
crystal structure (PDB ID: 4ASI, RCSB Protein Data Bank) (Figure 7C, Table 2).  In the human 
crystal structure and analogous mouse domains, O-GlcNAc sites were found in the central region 
(S966 and S976) and carboxyl transferase domain (S2091), implying that O-GlcNAc may 
regulate binding of protein partners in the central region (83) and/or the final step in the 
formation of malonyl CoA respectively, potentially altering ACC1 binding partner function or 
ACC1 catalytic activity directly.  To investigate whether O-GlcNAc might regulate ACC1 
activity, we looked at levels of phosphorylation of ACC1 at serine 79.  AMP kinase (5' 
49 
adenosine monophosphate-activated protein kinase) senses low ATP levels in a cell and inhibits 
ACC1’s energy intensive, biosynthetic activity by phosphorylating it at S79 (84).  We thus 
checked phospho-ACC1 levels over 0, 2, 4, 8, 16, and 24 hours after re-stimulation of naïve 
CD4+ T cells differentiated towards the Th17 lineage and found no significant changes in 
phospho-ACC1 levels (Figure 7D).  Thus, elevated O-GlcNAc does not increase the 
phosphorylation of ACC1 or alter AMPK inhibitory activity towards ACC1 in any appreciable 
way.   
Table 2. Murine ACC1 high confidence O-GlcNAc modified sites (analogous amino acid in 
human ACC1 crystal structure) 
S2091 (S2129)   S966 
S2285 (S2323)     S976 
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Figure 9.  Acetyl CoA carboxylase 1 (ACC1), the rate limiting enzyme of fatty acid 
biosynthesis, is modified by O-GlcNAc and TMG treatment does affect inhibitory 
phosphorylation by AMPK. A. ACC1 or O-GlcNAc modified proteins were 
immunoprecipitated from CD4+ T cells and show ACC1 is modified by O-GlcNAc.  B. 
Representative mass spectra plot of high confidence O-GlcNAc modified sites S966 and 
S976 on ACC1.  C. Location of analogous O-GlcNAc modified residues S2129 and 
S2323 in the carboxyl transferase domain on a purified human partial C-terminal crystal 
structure of ACC1.  D. Inhibitory phosphorylation of ACC1 at S79 is unchanged with 
TMG treatment over the 24 hours of re-stimulation. pACC1 and ACC1 levels were 
normalized to actin.  Blot is representative of 3 biological replicates.  Densitometry bars 
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Over-nutrition elevates CD4+ T cell O-GlcNAc levels, leading to increased pro-
inflammatory IL-17 cytokine production and enhanced risk for obesity-related pathology. 
In summary, we propose that over-nutrition elevates O-GlcNAc levels in naïve CD4+ T cells.  
ACC1 is O-GlcNAcylated and may be an initial mechanism driving the increased synthesis of 
saturated fatty acids and cholesterol biosynthetic intermediates which bind RORγt and increase 
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Figure 10.  Over-nutrition elevates CD4+ T cell O-GlcNAc levels, leading to 
increased pro-inflammatory IL-17 cytokine production and enhanced risk for 
obesity-associated pathology. Diseases of over-nutrition, such as obesity and diabetes, 
result in aberrantly increased O-GlcNAc levels in CD4+ T cells.  Elevated O-GlcNAc 
levels alter lipid metabolism in Th17 cells and favor formation of lipid ligands which 
increase RORγt activity at the IL-17 promoter.  Increased IL-17 levels raise the risk of 
pathological obesity-related sequelae, such as atherosclerotic plaque formation, cancer, 
and autoimmune diseases. 
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that drives insulin resistance, atherosclerotic plaque formation, and increases the risk for 


















CHAPTER 4: DISCUSSION 
Portions reprinted with permission from Machacek, M., Slawson, C., and Fields, P. E. (2018) O-
GlcNAc: a novel regulator of immunometabolism. Journal of Bioenergetics and Biomembranes.  
 
Obesity has reached epidemic proportions in the developed world and is increasingly becoming a 
problem in less developed nations (85).  Patients with diseases of over-nutrition, such as obesity 
and type 2 diabetes, have a well-defined chronic, low-grade inflammation.  This inflammation 
has been implicated in much of the downstream pathology associated with increased adiposity, 
such as atherosclerosis, insulin resistance, and increased risk of autoimmunity and cancer 
(65,67).  Thus, to lessen the morbidity, mortality, and financial burden consequent to obesity, it 
is imperative we better understand mechanisms that drive pathology related to excess adiposity.  
Among this chronic inflammatory milieu, CD4
+
 T cell effectors, particularly Th1 and Th17 cells, 
are critical players in the development of atherosclerotic plaques and infiltrate adipose tissue to 
mediate insulin resistance (64,67).  Unfortunately, mechanisms driving increased Th1 and Th17 
CD4+ T cells and their respective cytokines in the presence of excess nutrients are poorly 
understood.  In this study, we hypothesized that a homeostatic level of O-GlcNAcylation is 
necessary for the proper regulation of CD4+ T cell function and differentiation. Since O-GlcNAc 
levels are sensitive to environmental and nutritional changes, we further postulated that O-
GlcNAc would increase under conditions of over-nutrition and enhance pro-inflammatory 
function of CD4+ T cells, providing a mechanistic explanation for increased inflammation in 
diseases of over-nutrition.       
Major Findings 
 
To answer the question of how O-GlcNAc regulates CD4+ T cell function, we cultured murine 
CD4+ T cells with Thiamet-G (TMG), a highly specific O-GlcNAcase inhibitor, to disrupt 
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homeostatic O-GlcNAc levels.  We observed a significant increase in pro-inflammatory 
cytokines, IL-17A and IFNγ, major cytokines secreted by the Th17 and Th1 lineages 
respectively.  The most pronounced and significant effect by ELISA, intracellular cytokine 
staining, and analysis of RNA transcript levels was an effect on IL-17A.  Importantly, this effect 
on IL-17 was also observed with human CD4+ T cells, suggesting a similar mechanism is 
operational in humans.  Additionally, IL-23 receptor, another protein under transcriptional 
control of RORγt, had significantly elevated transcript levels.  IL-23R stabilizes the Th17 
phenotype and is one marker that defines a strongly pro-inflammatory, pathogenic Th17 cell 
phenotype (60).  Because of the strong effect of TMG on Th17 functional markers, we then 
isolated naïve CD4+ T cells and treated with TMG to elevate O-GlcNAc levels before activation 
and polarization towards the Th17 lineage.  Th17 cells differentiated ex vivo secreted 
significantly more IL-17 with TMG treatment and had a significantly increased albeit low 
percentage of cells secreting both IL-17 and IFNγ, another marker of increased pathogenicity 
(60,86).  A key characteristic of non-pathogenic Th17 cells is the production of both IL-17 and 
the immunosuppressive cytokine, IL-10, which is expressed abundantly by immunosuppressive 
regulatory T cells (Tregs) (60).  We observed no change in IL-10 protein or transcript levels in 
CD4+ T cells treated with TMG, suggesting no significant decrease in Tregs or non-pathogenic 
Th17 cells.  Additionally, we observed only a modest, though significant, 4% increase in the 
number of cells producing IL-17 with TMG treatment.  Overall, our data suggests a stronger 
effect of abnormally elevated O-GlcNAc resulting in more IL-17 being secreted per cell versus 
skewing differentiation towards Th17s at the expense of Tregs. 
With evidence of excess O-GlcNAcylation resulting in increased Th17 and Th1 inflammatory 
cytokines which are abnormally elevated in obesity, we wanted to determine O-GlcNAc’s role in 
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a Western diet (WD) fed mouse model.  In agreement with O-GlcNAc acting as a nutritional 
sensor, O-GlcNAc levels were significantly increased in the naïve CD4+ T cells of WD fed 
mice.  Interestingly, the levels of OGT and OGA were not different between mice fed standard 
chow (SC) and mice on the Western diet.  Normally, O-GlcNAc levels are vigorously maintained 
at a level particular for the needs of a cell (56).  For example, when O-GlcNAcylation is 
increased with TMG treatment, OGA levels will increase and OGT levels will decrease to return 
O-GlcNAc levels to baseline.  However, these results suggest that long-term nutritional excess 
causes O-GlcNAc levels to “reset” to an abnormally high level.  When this atypically high new 
set-point was pushed even further TMG treatment, both cells from SC and WD fed mice 
produced significantly more IL-17.  These results are in agreement with a known effect of a 
single nucleotide polymorphisms (SNPs) in the MGEA gene which encodes OGA. In a Mexican 
American population with these SNPs, OGA expression is decreased and there is increased 
incidence and earlier age of onset of type 2 diabetes (6).  Thus, O-GlcNAcylation is a mechanism 
contributing to increased pro-inflammatory IL-17 secretion, particularly relevant in the context 
of diseases of over-nutrition, where O-GlcNAc levels attain a higher homeostatic level.   
How does TMG treatment lead to increased IL-17A? After observing no changes in the protein 
and transcript levels of STAT3 and RORγt, two transcription factors critical in the differentiation 
of Th17 cells, we discovered that the lipid microenvironment was significantly altered.  Lipid 
ligands, such as sterols and saturated fatty acids, capable of binding and activating RORγt at the 
IL-17 locus were increased with TMG treatment.  Furthermore, we identified sites of O-
GlcNAcylation on acetyl CoA carboxylase 1 (ACC1), which provides the building blocks for 
both long chain fatty acid and cholesterol synthesis (87).  In addition to increased fatty acid and 
sterol products that result from ACC1 activity, two other lines of evidence suggest increased 
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ACC1 activity with TMG treatment.  First, palmitic acid (C16:0) is the first fatty acid produced 
as a result of ACC1 initiating fatty acid biosynthesis, and as such, negatively feedbacks to inhibit 
ACC1.  The significant decrease in palmitate with TMG treatment but significant increase in 
longer chain saturated fatty acids suggests palmitate is being rapidly diverted into elongation 
pathways or acylation of proteins and is thus less available to inhibit ACC1 activity.  
Additionally, we were unable to detect a change in inhibitory phosphorylation of ACC1 by 
AMPK at serine 79, so there is not increased inhibition of ACC1 with TMG treatment.  Of note, 
lipidomics analysis of endothelial cells treated with soraphen A, a potent inhibitor of ACC1, 
resulted in opposite effects of what we observed (88). With inhibition of ACC1, polyunsaturated 
fatty acids (PUFA) increased and phosphatidylglycerol (PG) decreased in endothelial cells, 
whereas we observed a significant decrease in PUFAs and increase in PG in our T cell model. In 
addition to an O-GlcNAc site (S2091) being present in the carboxyl transferase (CT) domain of 
ACC1, which catalyzes the final step of malonyl CoA formation, sites were found in the central 
region of ACC1 (S966 and S976).  In a crystal structure of yeast ACC1, the central region was 
found to be composed of 5 unique domains and was responsible for bringing the biotin 
carboxylase (BC) and CT domains together (89), which is an important step in catalysis. 
Importantly, deletion of residues 940-972 in the first domain of the central region abolished 
catalytic activity.  Overall, multiple lines of evidence suggest TMG treatment favors increased 
ACC1 activity and production of ligands which enhance RORγt activity.   
One final finding of interest from the lipidomics analysis, which provides further insight into 
how TMG treatment is broadly altering cellular metabolism, was a significant increase in 
ceramide and decrease in sphingomyelin.  Of particular relevance to our study, ceramide is well 
known to accumulate in obesity, specifically in liver, muscle, and adipose tissues (79) where it 
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suppresses insulin signaling pathways and promotes insulin resistance.  Thus, it is notable that 
we also observed an increase in ceramide in Th17 cells treated with TMG.  Multiple metabolic 
pathways feed into the production of ceramide, and of those, three are most relevant to our 
results. First, the de novo synthesis pathway begins with the transfer of serine to palmitoyl-CoA 
(79).  Since we observed a significant decrease in palmitate, this is potentially one pathway 
palmitate is being shunted towards.  Second, in the catabolic pathway, ceramide synthases 
convert sphingosine plus a fatty acid into ceramide.  Fatty acids of various chain lengths can be 
used to acylate ceramide.  Ceramide synthase 6 (CerS6) is the synthase responsible for 
specifically using palmitate in the synthesis of ceramide.  Importantly, CerS6 knock-out mice are 
resistant to weight gain and insulin resistance when fed a high fat diet  (90). Myeloid cell specific 
knock-out mice were not protected from weight gain or insulin resistance, but effects on 
lymphoid cells were not examined.  Interestingly, knock-out of CerS6 in splenocytes that were 
then adoptively transferred into a mouse colitis model led to maintenance of body weight and 
better pathology scores in the intestine (91).  However, the authors concluded it was most likely 
due to a decreased proliferative or migratory ability of the transferred T cells, since transferred T 
cells isolated from the lamina propria did not show a difference in Th17 and Treg percentage or 
IL-17 production.  Thus, the potential effects of CerS6 activity in T cells treated with TMG will 
require further study.  Finally, sphingomyelin found in the plasma membrane can be converted to 
ceramide by acid sphingomyelinase (ASM). Knockdown or pharmacological inhibition of ASM 
reduced IL-17 production from Th17 cells acquired from human patients with Crohn’s disease, 
an inflammatory bowel disease with increased Th7 function (92).  ASM increases IL-17 
production by associating with two human Th17 cell surface markers in the membrane, CD39 
and CD161, and increases their activation of mTOR and STAT3 pathways necessary for Th17 
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function.  In agreement with an important role for ASM in Th17 function, ASM-deficient mice 
have increased systemic Tregs (93,94).  Although we did not observe changes in STAT3 
signaling in murine CD4+ T cells, it is possible O-GlcNAc might play a clearer role in ASM 
function in human cells, which have better defined expression of CD161 and association with 
ASM.  Also of note, the conversion of ceramide to sphingomyelin requires phosphotidylcholine 
(79).  We observed a significant decrease in PC, which would suppress conversion of ceramide 
back to sphingomyelin.  Taken together, ceramide increases with TMG treatment are another 
indication of an inflammatory, obese phenotype and will require further investigation to fully 
understand the role it plays in our T cell model. 
Study Limitations 
 
Several limitations were present in this study.  First, our studies rely on use of pharmacological 
inhibition of OGA.  Thiamet-G (TMG) is highly specific for OGA, demonstrating 37,000 fold 
specificity for O-GlcNAcase compared to lysosomal hexosaminidase present in cells (95). 
However, off-target effects remain a possibility.  Genetic knock-out of OGT and OGA enzymes 
are embryonic lethal (96) and when conditionally knocked-out lead to cell death in proliferating 
cells (97,98).  This requirement of O-GlcNAcylation for cell proliferation makes it particularly 
difficult in studying T cell differentiation and function, since activation induces massive 
proliferation of T cells.   Thus, genetic manipulations to understand the role of O-GlcNAc often 
require identification of O-GlcNAc sites and then site-specific mutagenesis in a mouse model. 
We would like to perform such an experiment with ACC1 to determine the effects of O-GlcNAc 
on ACC1 and subsequent alterations to T cell function.  Second, our work relied on in vitro 
assays of T cell phenotype and function.  We have yet to determine if the enhanced IL-17 
secretion exacerbates or leads to inflammatory disease in vivo.  Furthermore, it would be 
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interesting to isolate Th17 cells infiltrating adipose or atherosclerotic plaques and compare to 
peripheral Th17s to see how O-GlcNAc/OGT/OGA levels change.  Finally, there is inherent 
difficulty in therapeutically targeting a post-translational modification that modifies thousands of 
proteins and is involved in many critical cellular processes, including transcription, translation, 
and cell cycle progression.  As the O-GlcNAc field progresses it is likely more site specific tools 
will be developed and there may be technologies developed for site-specific O-GlcNAc 
modulation, allowing us to therapeutically fine-tune O-GlcNAc. 
Future Directions 
 
As a post-translational protein modification exquisitely sensitive to changes in metabolic state 
and environmental factors, O-GlcNAc is poised as a major regulator of T cell function.  Based on 
our data demonstrating that elevated O-GlcNAcylation causes metabolic shifts that enhance 
Th17 function, what other functions might O-GlcNAc have in CD4
+
 T cell biology and in other 
cell types sensitive to similar metabolic changes? We propose three areas worth further 
investigation. 
First, a fascinating feature of CD4
+
 T cell subsets is their substantial plasticity.  For example, 
Th17 cells have two distinct functional states—a non-pathogenic state in which cells secrete both 
IL-17 and IL-10, an anti-inflammatory cytokine typical of iTregs, and a pathogenic state, in 
which cells secrete both IL-17 and IFNγ, the classical Th1 cytokine (99,100).  This dual 
Th17/Th1-like phenotype is linked to the pathogenesis of many autoimmune diseases, including 
multiple sclerosis, inflammatory bowel disease, and type 1 diabetes (60,86,100). Non-pathogenic 
Th17 cells convert to a pathogenic state when injected into a non-obese diabetic mouse model of 
type 1 diabetes, suggesting that abnormal metabolism may be involved in this conversion (86).  
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Further supporting a role for metabolic factors, the saturated to unsaturated fatty acid ratio in 
Th17 cells is critical for pathogenicity.  Increased saturated fatty acids due to a decreased 
expression of CD5L, a protein whose only previously known function was in macrophages, 
drove pathogenicity by creating ligands that specifically enhanced RORγt transcriptional activity 
at the IL-17 locus, while decreasing IL-10 transcriptional activity.  In future studies, it would be 
interesting to examine how O-GlcNAc might regulate critical nodes that shift plasticity, such as 
CD5L, and ways this could be altered therapeutically as a molecular switch of cellular states. 
Second, pro-inflammatory Th1 and Th17 cells critically drive many autoimmune diseases.  As 
mentioned previously, aberrant OGT levels have been implicated in promoting inflammatory T 
cells in multiple sclerosis and systemic lupus erythematosus (SLE) (4,5).  Additionally, 
disruptions in metabolic pathways of T cells have been implicated in autoimmune inflammation, 
which could lead to increased shunting of metabolites into the hexosamine biosynthetic pathway, 
fueling O-GlcNAcylation.  For example, inappropriate, chronic stimulation of the PI3K-AKT-
mTOR signaling pathway leads to the accumulation of inflammatory Th17 cells in SLE (101).  
Synovial infiltrating inflammatory T cells in rheumatoid arthritis have decreased glycolytic flux 
at the rate-limiting step, shunting substrates towards the pentose phosphate pathway (PPP) (102).  
Increased PPP flux increases production of NADPH, an essential reductant for fatty acid 
synthesis, thought to drive abnormal fatty acid metabolism and formation of intracellular lipid 
droplets.  In addition to increased shunting to the PPP, it seems likely that impaired glycolysis 
might also increase flux through the HBP and abnormally elevate O-GlcNAcylation.  Thus, 
determining the exact role of O-GlcNAc regulation in autoimmune T cells could lead to fruitful 
insight into pathogenic mechanisms driving autoimmune CD4
+
 T cell inflammation. 
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Finally, an effect of elevated O-GlcNAcylation on increasing cellular ceramide levels could have 
broad implications for tissues involved in insulin resistance and atherosclerosis.  Insulin 
signaling activates protein kinase B (also known as Akt), which then phosphorylates multiple 
substrates with the effect of increasing glucose uptake and metabolic programs involved in cell 
growth and survival (103).  Critically, ceramide blocks protein PKB activation by promoting 
phosphorylation events that prevent its localization to the membrane and removal of inhibitory 
phosphorylation (104,105).  Interestingly, PKB is O-GlcNAcylated and elevated O-
GlcNAcylation also contributes to insulin resistance by blocking PKB phosphorylation (106).  In 
future studies, it would be interesting to more clearly tease out the interplay between O-GlcNAc, 
ceramide, and insulin signaling proteins.  Increased ceramide levels are also pathogenic in heart 
disease.  For example, increased ceramide promotes retention of oxidized low-density 
lipoprotein (ox-LDL) in the atherosclerotic plaque (107), a critical step in recruiting 
macrophages and inflammatory T cells.   In individuals with unstable angina or acute myocardial 
infarction, blood levels of ceramide and activity of acid sphingomyelinase are increased, but then 
fall after restoration of blood flow (108).  Thus beyond exploring the effects of increased 
ceramide in T cells, it would be of value to better understand if and how O-GlcNAc promotes 
ceramide production in the vasculature and insulin responsive organs, such as skeletal muscle, 
adipose, and liver.  
Conclusion 
 
Obesity and diabetes are major public health concerns and the immune system is a critical driver 
of pathogenesis in these diseases.  Intervening at the level of inflammation is of critical 
importance in preventing pathological complications.  Unfortunately, the mechanisms driving 
chronic inflammation have been difficult to elucidate.  The results of this study represent the first 
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investigation of how the O-GlcNAc post-translational modification regulates CD4+ T cell 
function and differentiation and support a role for aberrant O-GlcNAcylation in mediating a pro-
inflammatory Th17 response in a type 2 diabetic mouse model.  Human CD4+ T cells showed a 
similar significant increase in IL-17 production when treated with TMG.  Thus, mechanistic 
insights derived from murine CD4+ T cells may be applicable to humans.  Importantly, we 
discovered that the rate-limiting enzyme in fatty acid biosynthesis, ACC1, is O-GlcNAcylated 
and the lipid profile of cells treated with TMG shifts towards an inflammatory phenotype and 
produces ligands driving RORγt transcriptional activity at the IL-17 locus.  This works thus fills 
in a piece of the mechanistic puzzle for why inflammatory cytokine production increases in 
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